EHA data the final nail in the coffin for Gilead’s magrolimab

17 June 2024

New data has laid bare the reasons why US biotech Gilead Sciences (Nasdaq: GILD) has given up on magrolimab, a monoclonal antibody that targets CD47, an antiphagocytic signal present on cancer cells.

The California-based company removed remaining solid tumor trials of magrolimab from its pipeline in April, despite the drug being the main factor for the firm’s $4.9 billion buy of Forty Seven in 2020.

From the latest data coming out of a Phase III study presented at 2024’s European Hematology Association (EHA) meeting, it appears that Gilead had little choice.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK